Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pritelivir→

Pritelivir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
348086-71-5
Molecular formula
C18H18N4O3S2
Molecular weight
402.49 g/mol
Drug class
Investigational antiviralherpes simplex virus (HSV) helicase-primase inhibitor
Mechanism of action
Inhibits the HSV helicase-primase complex, preventing viral DNA unwinding and replication. This mechanism is distinct from nucleoside analogues such as acyclovir.
Indications / reported uses
  • Investigational oral treatment studied for acyclovir-resistant or acyclovir-refractory HSV infection, including in immunocompromised adults; pritelivir should not be represented as an approved routine therapy.

Sources: https://pubmed.ncbi.nlm.nih.gov/42751311/ · https://clinicaltrials.gov/search?term=pritelivir · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pritelivir Environmental Risk Assessment (ERA) (the Pritelivir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.